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Available online 22 November 2015Background: Cerebrospinal ﬂuid (CSF) neuroﬁlament light chain protein (NFL) is a sensitive marker of neuronal in-
jury in a variety of neurodegenerative conditions, including the CNS dysfunction injury that is common in untreated
HIV infection. However, an important limitation is the requirement for lumbar puncture. For this reason, a sensitive
and reliable bloodbiomarker of CNS injurywould represent awelcomeadvance in both clinical and research settings.
Methods: To explore whether plasma concentrations of NFL might be used to detect CNS injury in HIV infection, an
ultrasensitive Single molecule array (Simoa) immunoassay was developed. Using a cross-sectional design, we mea-
suredNFL inpairedCSF andplasma samples from121HIV-infected subjects divided into groups according to stage of
their systemic disease, presence of overt HIV-associated dementia (HAD), and after antiretroviral treatment (ART)-
induced viral suppression. HIV-negative controls were also examined.
Findings: Plasma andCSFNFL concentrationswere very highly correlated (r=0.89, P b 0.0001).WhileNFLwasmore
than 50-fold lower plasma than CSF it was within the quantiﬁable range of the new plasma assay in all subjects, in-
cluding the HIV negatives and the HIV positives with normal CSF NFL concentrations. The pattern of NFL changes
were almost identical in plasma and CSF, both exhibiting similar age-related increases in concentrations along
with highest values in HAD and substantial elevations in ART-naïve neuroasymptomatic subjects with low blood
CD4+ T cells.
Interpretation: These results show that plasma NFL may prove a valuable tool to evaluate ongoing CNS injury in HIV
infection thatmay be applied in the clinic and in research settings to assess the presence if active CNS injury. Because
CSF NFL is also elevated in a variety of other CNS disorders, sensitive measures of plasma NFL may similarly prove
useful in other settings.
© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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Infection of the central nervous system (CNS) is a nearly universal
feature of systemic human immunodeﬁciency virus-1 (HIV) infection.
It develops early in systemic HIV infection (Valcour et al., 2012) and
continues throughout its untreated course (Gisslen et al., 1999). While
often seemingly innocent, this infection can evolve to a form that is as-
sociated with CNS injury, most severely manifesting as HIV-associatediseases, Sahlgrenska University
. This is an open access article underdementia (HAD) with high morbidity and mortality (Price et al.,
1988). However, infected individuals can also manifest less severe CNS
injury that elides detection (Antinori et al., 2007; Heaton et al., 2011).
Individuals with HIV infection can suffer CNS dysfunction from a variety
of other conditions that can confuse diagnosis. Current research diag-
nostic classiﬁcation depends on performance on a neuropsychological
test battery which may be difﬁcult to implement and also can be con-
founded by other conditions and co-morbidities (Antinori et al., 2007).
Moreover, in patients with neurocognitive impairment it may be difﬁ-
cult to distinguish ongoing CNS injury related to HIV infection from
prior but now static CNS injury, particularly without clear longitudinal
observation. In order to more objectively deﬁne ongoing CNS injury inthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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incidence of CNS disease or CNS treatment effects, sensitive and reliable
objective biomarkers can prove to be of great value.
To date, measurement of neuroﬁlament light chain (NFL) concentra-
tions in the cerebrospinal ﬂuid (CSF) appears the most sensitive and
useful biomarker of active CNS injury in HIV infection— showing eleva-
tions in not only overt HAD but also in patients with less severe, inap-
parent or clinically confounded impairment (Jessen Krut et al., 2014;
Peterson et al., 2014). However, the need to sample CSF has limited
the application of thismeasurement, particularly in the clinical contexts
of screening patients, assessing those who refuse lumbar puncture, or
evaluating those who suffer other conditions that obscure evaluation.
An assay that could be applied more broadly to cohort studies and clin-
ical trials that do not include lumbar puncture would also be valuable in
assessing the prevalence of CNS injury and its response to treatment.
Hence, a biomarker requiring only blood sampling rather than lumbar
puncture would clearly represent a useful advance in clinical manage-
ment and research settings.
To address this needwe have developed an ultra-sensitive immuno-
assay for plasma NFL using Single molecule array (Simoa) technology
(Rissin et al., 2010). In this studywe compare plasmawith CSF NFL con-
centrations of NFL in a cross-sectional study of HIV-infected individuals
and HIV-negative controls and show that the plasma analysis using this
sensitive method yields results that are concordant with CSF analysis
despite the differences of NFL concentrations in the two ﬂuids.
2. Methods
2.1. Study Design and Patients
This was a cross-sectional study using archived blood and CSF sam-
ples originated from two cohort studies: one in Gothenburg, Sweden
and the second in San Francisco, California. The samples and related
background data were all obtained between 1992 and 2014 within the
context of research protocols approved by the institutional review
boards of the two study sites. All blood and CSF samples were obtained
after informed consent of subjects under these IRB-approved protocols.
Blood and CSF were included from 7 deﬁned HIV-infected subject
groups (n = 121) as outlined in previous studies (Jessen Krut et al.,
2014; Peterson et al., 2014): early or ‘primary’ HIV infection (PHI, de-
ﬁned as within the ﬁrst twelve months after initial HIV-1 infection)
(Spudich et al., 2011); four groups of chronically HIV-infected subject
volunteers without a diagnosis of HAD and who were not being eval-
uated or treated for overt neurological symptoms or signs when re-
cruited, designated as neuroasymptomatic (NA) and divided by
blood CD4+ T cell counts into those with N350, 200–349, 50–199,
and CD4 b 50 cells/μL; and a group presenting with clinically overt
HAD, most commonly of subacute onset. All of these subjects were
either naïve to treatment or off treatment for at least 6 months at
the time of sampling. Also included was a group of treated HIV-
infected subjects with N1 year of plasma virus suppression to below
50 copies/mL of HIV RNA (ART). A group of uninfected (HIV-neg)Table 1
Background Subject Characteristics.
Groups N Age
Median years (IQR)
HIV negative (HIV-neg) 19 34 (29–48)
Primary HIV Infection (PHI) 13 36 (30–46)
Neuroasymtpomatic HIV (NA)
CD4 N 350 19 41 (35–43)
CD4 200–349 17 48 (36–56)
CD4 50–199 19 44 (37–56)
CD4 b 50 20 41 (36–49)
HIV-associated dementia (HAD) 11 43 (38–56)
HIV, treated-suppressed (ART) 22 44 (38–52)volunteer subjects (n = 19), conﬁrmed by serological testing at study
visit, were recruited from the San Francisco community for research as-
sessments to provide comparison data for the HIV-infected subjects.
Background clinical, laboratory and demographic data for each subject
group are summarized in Table 1.
2.2. Blood and CSF Sampling
Blood and CSF were obtained according to standard protocols as
previously described (Price et al., 2001; Gisslen et al., 2007). CSFwas im-
mediately subjected to low-speed centrifugation to remove cells,
aliquoted and stored within 1 h of collection at ≤−70 °C until the time
of the neuronal biomarker assays. Blood was collected in EDTA tubes
and plasma was aliquoted and stored in parallel with CSF for later
batch assays.
2.3. Background Laboratory Methods
We explored correlations with background HIV clinical biomarkers
including: blood CD4+ T cell counts: CSF and blood HIV RNA concentra-
tions; CSF white blood cell (WBC) counts; CSF:serum albumin ratio as
an indicator of blood–brain barrier permeability; and blood and CSF
neopterin, a marker of macrophage and microglial activation (Hagberg
et al., 2010).
HIV RNA levels were measured in cell-free CSF and plasma at
each site using the Cobas TaqMan RealTime HIV-1 (version 1 or
2; Hoffmann-La Roche, Basel, Switzerland), or the Abbott RealTime
HIV-1 assay (Abbot Laboratories, Abbot Park, IL, USA). All recorded
viral loads that were below the lower limit of quantitation (40
copies/mL) were standardized to a deﬁned ‘ﬂoor’ value of 20 cop-
ies/mL for descriptive purposes. Blood and CSF neopterin were an-
alyzed using a commercially available immunoassay (BRAHMS,
Hennigsdorf, Germany), with an upper normal reference value of
8.8 nmol/L in blood and 5.8 nmol/L in CSF (Hagberg et al., 2010).
Each study visit included assessments by local clinical laboratories
using routine methods to measure CSF white blood cell (WBC) count,
CSF and blood albumin, and blood CD4+ andCD8+ T lymphocyte counts
by ﬂow cytometry.
2.4. Clinical Evaluations
All HIV-infected subjects and controls underwent routine clinical
bedside screening for symptomsor signs of CNS opportunistic infections
or other conditions that could impact CSF or blood biomarker concen-
trations. Diagnosis of HAD was based on clinicians' assessment at pre-
sentation which was characteristically subacute, and met American
Academy of Neurology criteria (Anon., 1991). Many of these subjects
were studied before publication of the more formal Frascati criteria
(Antinori et al., 2007) andwere diagnosedwith AIDS dementia complex
(ADC) stages 1–4 (Price and Brew, 1988) but met the functional criteria
for the Frascati diagnosis of HADwithout the requisite extensive formal
neuropsychological assessment.Plasma HIV-RNA CSF HIV-RNA Blood CD4+ T cells
Median Log10 (IQR) Median Log10 (IQR) Median cells/mL (IQR)
NA NA 763 (686–993)
4.70 (4.11–5.64) 2.73 (1.96–3.94) 539 (340–761)
4.08 (3.30–4.44) 3.23 (2.45–3.68) 490 (402–582)
4.91 (4.30–5.31) 4.28 (3.44–4.68) 240 (215–305)
4.97 (4.44–5.25) 3.96 (3.53–4.56) 125 (100–170)
5.40 (4.54–5.88) 3.10 (2.30–3.81) 22 (10–39)
5.49 (4.83–5.83) 4.34 (2.59–5.31) 60 (30–144)
1.30 (1.30–1.30) 1.30 (1.30–1.30) 544 (275–725)
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CSF NFL concentrations were measured using a sensitive sandwich
method (NF-light® ELISA kit, UmanDiagnostics AB, Umeå, Sweden) as
previously described (Jessen Krut et al., 2014; Norgren et al., 2003).
The coefﬁcient of variations (CVs) for the repeatability and intermediate
precision for this assay is CV b 6% and CV b 7%, respectively, and the
lower limit of quantiﬁcation (LLOQ) is 50 pg/mL determined by repeat-
ed measurements (n = 15) of a CSF sample with low (52 pg/mL)
concentration and still acceptable variability (CV = 12%). Plasma NFL
levels were determined using the same monoclonal antibodies and cal-
ibrator as in the NF-light assay, transferred onto the Simoa platform
using a homebrew kit (Quanterix, Lexington, MA, USA). The limit of de-
tection (mean blank signal + 3 SD) for the Simoa NFL assay was
0.3 pg/mL and the lower limit of quantiﬁcation (mean blank signal+10
10 SD) was 2.7 pg/mL when compensated for a four-fold sample dilu-
tion. Samples were analyzed in duplicate, and the CV for the samples
was below 10%.
All plasma sampleswere analyzed in a single run in the Laboratory of
Neurochemistry at the University of Gothenburg by board-certiﬁed lab-
oratory technicians blind to clinical data using a single batch of reagents
for each assay; intra-assay coefﬁcients of variation were below 10% for
all analyses. Previously described laboratory cutoffs for CSF NFL were
used for descriptive analysis (Jessen Krut et al., 2014). Based on age-
related reference values, normal cutoff values in CSF for NFL were de-
ﬁned as b380 ng/L (b30 years), b560 ng/L (30–39 years), b890 ng/L
(40–59 years), and b1850 ng/L (N59 years). Laboratory cutoffs for
blood NFL have not yet been deﬁned. Some of the CSF NFL results and
results of the PHI subjects have been previously reported in a different
context (Peterson et al., 2014; Peluso et al., 2013), including within aFig. 1.Association between CSF and plasmaNFL and concentrations of biomarkers in 8 subject g
HIV-negative controls (HIV-neg); primary HIV infection (PHI); untreated neuroasymptomatic su
on suppressive antiretroviral treatment (ART). Boxes depict median and IQR, whiskers show 10
the limit of detection for HIV RNA (40 copies/mL), and in panel f the upper limit of normal for CSlarger data set characterizing CSF in relation to age (Jessen Krut et al.,
2014).
2.6. Statistical Methods
Descriptive statistics were performed using Prism (version 6,
Graphpad Software Inc., La Jolla, CA) or SPSS (IBM SPSS version 21) soft-
ware. Continuous variables were log10 transformed where appropriate
to reduce skewness. Comparison of biomarker concentrations was per-
formedwith One-way ANOVA and Tukey's multiple comparison test for
evaluation of multiple groups. Biomarker associations were analyzed
with Pearson correlation analysis. The relationship between age and
log10 plasma and CSF NFL levels, was analyzed with linear regression.
3. Results
PlasmaNFL concentrations were within the linear range of the assay
in all samples, Fig. 1a. It was thus possible to quantify plasma NFL in all
subjects analyzed, despite more than 50-fold lower concentrations than
in CSF. This included the HIV-negative controls and other subjects with
low normal CSF NFL levels, Table 2. CSF concentrations were likewise
within the quantitative range of the standard assay, Fig. 1b. Notably,
plasma NFL concentrations were highly correlated with those of CSF
(r = 0.89, p b 0.0001), Fig. 1c. Fig. 1 provides general context for the
NFL results, showing plasma and CSF HIV RNA (d and e) and CSF
neopterin (f) concentrations are also shown in Fig. 1.
The patterns of plasma and CSF NFL concentration changes across
the HIV-infected groups were very similar. In agreement with previous
studies, the CSF NFL elevations were greatest in the HAD groups but
there was also a high prevalence of abnormal levels in untreatedroups. Panels a–b and d–f, plot concentrations of differentmarkers for the 8 subject groups,
bjects in different CD4 cell strata (Asympt); HIV-associated dementia (HAD); and subjects
–90 percentiles and ‘+’ designates the means. Dotted horizontal lines in panels d–e show
F neopterin (5.8 nmol/L). Panel c plots the correlation between log CSF and log plasmaNFL.
Table 2
Median (IQR) Plasma NFL (Left Columns) and CSF NFL (Right Columns) Concentrations in
Different Groups.
Groups N Plasma NFL CSF NFL
Median nmol/L
(IQR)
Median nmol/L
(IQR)
HIV negative (HIV-neg) 19 9.3 (5.9–13.1) 363 (264–487)
Primary HIV Infection (PHI) 13 11.2 (8.2–16.6) 732 (456–1288)
Neuroasymtpomatic HIV (NA)
CD4 N 350 19 9.0 (6.5–14.3) 488 (374–694)
CD4 200–349 17 9.7 (7.6–12.2) 573 (464–764)
CD4 50–199 19 12.1 (7.8–44.7) 640 (490–1530)
CD4 b 50 20 39.6 (12.0–103) 2415 (690–4420)
HIV-associated dementia (HAD) 11 114 (46.0–235) 16,185 (1513–43,010)
HIV, treated-suppressed (ART) 22 11.1 (8.6–12.8) 582 (322–706)
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et al., 2014; Peterson et al., 2014). Using the laboratory age-related
cut-offs for CSF NFL, all of the HAD patients had elevated CSF NFL
concentrations, and 75% of untreated neuroasymptomatic subjects
with CD4+ T-cell count below 50 cells/μL and 58% with 50–199 CD4+
cells/μL had abnormal CSF NFL concentrations; additionally 24% of sub-
jects with 200–349 CD4 cells and 16% of those with CD4 cell counts
above 350 cells/μL had increased levels—indicating a high level of
clinically unappreciated ongoing CNS injury that varied with degree of
systemic disease progression. By comparison, in the treated group,
and in HIV-negative subjects, the frequency was much lower, 4 and
5%, respectively. There also were moderate elevated CSF NFL levels in
a large proportion of subjects with PHI, 54%, in accordance with previ-
ous reports (Spudich et al., 2011).
Unlike CSF, age-related reference values have not yet been
established for plasma NFL, but the pattern of changes in the subject
groups was very similar to that of CSF NFL. Again the HAD had highest
plasma NFL concentrations, with all values exceeding the 90th percen-
tile of the HIV negative control levels. Like CSF, there were also eleva-
tions of plasma NFL in a substantial portion of the neuroasymptomatic
subjects with low CD4+ T cell counts.
The reason for the similarity in these patterns was the strong corre-
lation between plasma and CSF NFL (Fig. 1c) and thus the plasma levels
appear to reﬂect concentrations in CSF and, hence, the severity of CNS
injury.
Statistical comparisons between groups usingOne-wayANOVAwith
Tukey's multiple comparison tests are listed in Table 3. The plasma and
CSF NFL concentrations in the HAD group were signiﬁcantly elevated
compared to all other subgroups. The neuroasymptomatic CD4 b 50
group were also elevated above the other groups, except compared toTable 3
Comparisons of Blood and CSF Neuroﬁlament Light Protein (NFL) Concentrations Among
Subject Groups.
Blood NFL (log) CSF NFL (log)
Overall ANOVA p
Group Comparisons b0.0001 b0.0001
Tukey's Multiple Comparison
HAD vs. HIV- b0.0001 b0.0001
HAD vs. PHI b0.0001 b0.0001
HAD vs. NA CD4 N 350 b0.0001 b0.0001
HAD vs. NA CD4 200–349 b0.0001 b0.0001
HAD vs. NA CD4 50–199 b0.0001 b0.0001
HAD vs. NA CD4 b 50 0.008 b0.0001
HAD vs. ART b0.0001 b0.0001
NA CD4 b 50 vs. HIV- b0.0001 b0.0001
NA CD4 b 50 vs. PHI 0.005 0.063
NA CD4 b 50 vs. NA CD4 N 350 b0.0001 0.001
NA CD4 b 50 vs. NA CD4 200–349 b0.0001 0.001
NA CD4 b 50 vs. NA CD4 50–199 0.056 0.129
NA CD4 b 50 vs. ART b0.0001 b0.0001neuroasymptomatic CD4 50–199, and, for CSF only, also to the PHI
group.
CSF NFL increases with age in the absence of HIV infection (Jessen
Krut et al., 2014) and, as anticipated, there was a signiﬁcant correlation
between age and CSF NFL in the group of 19 HIV-negative controls
(r = 0.67, p = 0.002). Similarly, plasma NFL was strongly associated
with age in HIV-negative controls (r = 0.79, p b 0.0001). In Fig. 2,
plasma (b) and CSF (c) NFL are plotted against age in the different
groups studied. The slopes of the plasma and CSF NFL values against
age in HIV-negative controls were similar to what has been reported
previously in CSF (Jessen Krut et al., 2014), Fig. 2a.
Plasma and CSF NFL were also signiﬁcantly correlated with CD4+ T
cell count, plasma and CSF HIV RNA levels, blood and CSF neopterin,
and the albumin ratio. Correlation coefﬁcients were similar for CSF
and plasma NFL (Table 4).
4. Discussion
A sensitive and reliable blood biomarker of neural injury in CNS
neurodegeneration has long been sought. The results of this study
show that plasma levels of NFL provide a good indicator of active
CNS injury in HIV infection that agrees well with the results of CSF
NFL measurement. This thus promises to be a useful advance in the
study of CNS injury in HIV infection. Additionally, because of the sensi-
tivity of CSF NFL to CNS injury in other settings, these ﬁndings suggest
that this same assay may be useful also in other neurodegenerative
conditions.
Using an ultrasensitive immunoassay, NFLwas detectable and quan-
tiﬁable in blood in all subjects analyzed despitemore than 50-fold lower
concentrations than in CSF. This included detection in subjects with low
normal CSF NFL levels, including HIV-negative controls and HIV-
infected on suppressive ART. Thus, the assay could be used to analyze
the full range of subjects included in this study and could be similarly
deployed in other small and large clinical and research settings to assess
active CNS injury.
We found elevated levels of NFL, both in CSF and plasma, in patients
with HAD and in some neuroasymptomatic HIV-infected patients,
mainly in subjects with low CD4+ cell count. This is in agreement
with previous studies on CSF NFL, reﬂecting an ongoing subclinical axo-
nal injury in these subjects (Jessen Krut et al., 2014). CSF NFL can predict
subsequent development of HAD and we have previously shown that
CSF NFL was increased 1–2 years before overt symptoms of dementia
in patients developing HAD in the pre-ART era (Gisslen et al., 2007).
The incidence of HAD has decreased substantially during recent years
in the developed world when the majority of HIV-infected patients
are on effective ART (Lescure et al., 2011). Nowadays, HAD develops
almost exclusively in so called late presenters with low CD4+ T cell
counts at time of diagnosis. ART effectively prevents HAD, and severe
neurocognitive disease rarely develops in patients on effective ART.
Exceptions are rare cases with ‘neurosymptomatic CSF escape’ charac-
terized by new progressive CNS disease in patients on ART with unde-
tectable or low HIV RNA in plasma but disproportionately increased
viral loads in CSF (Canestri et al., 2010; Peluso et al., 2012). Although
CSF NFL can be used to detect active neuronal injury in these settings,
it is limited by the need for CSF sampling that sometimes could be an
obstacle. While more severe CNS disease is uncommon in treated HIV,
mild neurocognitive impairment is frequently found also in patients
on ART (Antinori et al., 2007; Heaton et al., 2010). In these treatment
settings, plasma NFLmay be a useful marker to help discriminate active
ongoing neuronal injury from neurological or cognitive symptoms re-
lated to sequelae of prior CNS damage that occurred before treatment
initiation (Munoz-Moreno et al., 2008), so called inactive disease,
though this important issue needs further direct study. This distinction
between active and static injury may have important implications for
treatment, the ﬁrst more amenable to intervention either with addi-
tional antiviral or adjuvant, anti-inﬂammatory, interventions. Previous
Fig. 2. Association between NFL and age. Panel a displays the regression lines for age to log plasma and log CSF NFL in HIV-negative controls. Age was closely correlated with plasma NFL
(r = 0.79, p b 0.0001).
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individuals may have been underpowered because of failure to distin-
guish between active and static neural injury. Importantly, a plasma
assay of injury might prove valuable to assess neurological impact of
treatment trials that have not included neurological assessments or
lumbar puncture, opening a large experience with different treatment
strategies and drug regimens to neurological outcome analysis.
Increased concentrations of CSF NFL are not speciﬁc to HIV-related
brain damage; CSF NFL levels have been shown to be a sensitive indica-
tor of CNS axonal injury in several neurological diseases (Norgren et al.,
2003; Constantinescu et al., 2010; Gunnarsson et al., 2011) including
various infections (Studahl et al., 2000; Grahn et al., 2013), and, by ex-
trapolation, plasma NFL has the potential to become a valuable marker
in a wide range of neurological disease settings.
Plasma NFL increased with age in our controls in a pattern similar to
that found in the CSF. This age-dependent increase in CSF NFL has been
clearly deﬁned in earlier, larger studies (Jessen Krut et al., 2014). The
mechanisms underlying the age-dependent increase in CSF NFL have
not been established, but these age effects need to be considered
when analyzing NFL concentrations, including the effects of treatment
in individuals with HIV followed over longer periods of time.
NFL is important for maintenance of the axonal caliber andmorpho-
logical integrity and is expressed predominantly in large-caliber mye-
linated axons (Hoffman et al., 1987), but is also present in neurites
(axons and dendrites) of CNS neurons in the cerebral and cerebellar cor-
tex, hypothalamus and spinal cord (Trojanowski et al., 1986). Its CSF
levels reﬂect leakage from injured or degenerating neurons, correlate
withwhite-matter lesions andother injuries to subcortical brain regions
(Jonsson et al., 2010), and predict severity and survival in several neuro-
degenerative diseases (Skillback et al., 2014). The robust correlation be-
tween plasma and CSF levels of NFL strongly suggests that plasma levels
indeed reﬂect ongoing CNS injury, which is in agreement with a recent
study on amyotrophic lateral sclerosis, however using a less sensitive
method that does not allow proper quantiﬁcation in all samples (Lu
et al., 2015). However, an increase in plasma NFL without adjacent in-
crease in CSF could theoretically also be a result of peripheral neuronal
injury given that NFL is also found in peripheral nervous system neu-
rons (Trojanowski et al., 1986). The magnitude of this effect needs to
be evaluated in future studies of patients with the common HIV distal
sensory and other neuropathies.Table 4
Plasma NFL (Left Columns) and CSF NFL (Right Columns) Correlation With Background
HIV Clinical Biomarkers.
Log Plasma NFL Log CSF NFL
r p r p
Log CD4 −0.43 b0.001 −0.36 b0.001
Log P HIV RNA 0.45 b0.001 0.41 b0.001
Log CSF HIV RNA 0.25 0.020 0.29 0.008
Log S Neopterin 0.48 b0.001 0.44 b0.001
Log CSF Neopterin 0.42 b0.001 0.30 0.002
Log CSF/P albumin ratio 0.31 0.004 0.30 0.002We have observed a close correlation between plasma and CSF
NFL, including a parallel increase in both, in the presence of ongoing
neuronal injury in HIV-infected patients. Therefore, we believe that
plasma NFL has the potential of being a useful biomarker of CNS injury
in HIV infection, and most likely in other neurodegenerative settings as
well.
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